Diluted earnings per ADS were $0.18, which compares with $0.26 in the second quarter of 2010.
Non-GAAP diluted earnings per ADS were $0.25, which compares with $0.28 in the second quarter of 2010.
Financial Position As of June 30, 2011, the Company had cash and cash equivalents of $41.6 million and short term debt of $0.8 million. During the quarter, capital expenditures totaled $11.0 million, including $5.5 million related to the purchase of a 68,000 square foot new lab and office building which replaced the original 36,000 square foot facility in Chengdu. The purchased lab and office building allows us to reduce overall expenditures and improve our earnings over time. With a strong balance sheet and sound financial position, the Company is well positioned to make targeted investments when opportunities arise.
Full Year 2011 GuidanceThe Company reconfirms its guidance for full year 2011. The Company expects:
This reflects the Company's current view and is subject to change.
Conference CallShangPharma will host a conference call and live webcast at 8am New York time on August 22, 2011 (8pm Beijing time on August 22, 2011). A PowerPoint presentation accompanying the prepared remarks will be available on the Company's website shortly before the call.
The dial-in details
|SOURCE ShangPharma Corporation|
Copyright©2010 PR Newswire.
All rights reserved